TW200510424A - Treatment of male sexual dysfunction - Google Patents
Treatment of male sexual dysfunctionInfo
- Publication number
- TW200510424A TW200510424A TW093121513A TW93121513A TW200510424A TW 200510424 A TW200510424 A TW 200510424A TW 093121513 A TW093121513 A TW 093121513A TW 93121513 A TW93121513 A TW 93121513A TW 200510424 A TW200510424 A TW 200510424A
- Authority
- TW
- Taiwan
- Prior art keywords
- treatment
- sexual dysfunction
- male sexual
- ejaculation
- relates
- Prior art date
Links
- 206010057672 Male sexual dysfunction Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 206010036596 premature ejaculation Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000000908 Vasopressin V1A receptors Human genes 0.000 abstract 1
- 108050007942 Vasopressin V1A receptors Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0317227.7A GB0317227D0 (en) | 2003-07-23 | 2003-07-23 | Treatment of male sexual dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200510424A true TW200510424A (en) | 2005-03-16 |
Family
ID=27772516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW093121513A TW200510424A (en) | 2003-07-23 | 2004-07-19 | Treatment of male sexual dysfunction |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1656183B1 (https=) |
| JP (1) | JP2006528171A (https=) |
| AT (1) | ATE380048T1 (https=) |
| BR (1) | BRPI0412255A (https=) |
| CA (1) | CA2533177A1 (https=) |
| CL (1) | CL2004001702A1 (https=) |
| GB (1) | GB0317227D0 (https=) |
| MX (1) | MXPA05014200A (https=) |
| TW (1) | TW200510424A (https=) |
| UA (1) | UA79674C2 (https=) |
| WO (1) | WO2005006899A1 (https=) |
| ZA (1) | ZA200505957B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117414361A (zh) * | 2023-09-28 | 2024-01-19 | 华中农业大学 | 一种化合物在预防和治疗革兰氏阴性菌病方面的应用 |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| GB0504556D0 (en) * | 2005-03-04 | 2005-04-13 | Pfizer Ltd | Novel pharmaceuticals |
| WO2006100557A1 (en) * | 2005-03-21 | 2006-09-28 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
| US20220152032A1 (en) * | 2020-11-13 | 2022-05-19 | Pharma America Holding Inc. | Sexual therapy formulation and method of treatment |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2000223275A1 (en) * | 2000-02-08 | 2001-08-20 | Yamanouchi Pharmaceutical Co..Ltd. | Novel triazole derivatives |
| GB0224919D0 (en) * | 2002-10-25 | 2002-12-04 | Pfizer Ltd | Triazole compounds useful in therapy |
-
2003
- 2003-07-23 GB GBGB0317227.7A patent/GB0317227D0/en not_active Ceased
-
2004
- 2004-07-06 CL CL200401702A patent/CL2004001702A1/es unknown
- 2004-07-12 JP JP2006520920A patent/JP2006528171A/ja not_active Abandoned
- 2004-07-12 AT AT04743961T patent/ATE380048T1/de not_active IP Right Cessation
- 2004-07-12 BR BRPI0412255-0A patent/BRPI0412255A/pt not_active IP Right Cessation
- 2004-07-12 EP EP04743961A patent/EP1656183B1/en not_active Expired - Lifetime
- 2004-07-12 CA CA002533177A patent/CA2533177A1/en not_active Abandoned
- 2004-07-12 WO PCT/IB2004/002300 patent/WO2005006899A1/en not_active Ceased
- 2004-07-12 MX MXPA05014200A patent/MXPA05014200A/es unknown
- 2004-07-19 TW TW093121513A patent/TW200510424A/zh unknown
- 2004-09-02 UA UAA200508142A patent/UA79674C2/uk unknown
-
2005
- 2005-07-25 ZA ZA200505957A patent/ZA200505957B/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117414361A (zh) * | 2023-09-28 | 2024-01-19 | 华中农业大学 | 一种化合物在预防和治疗革兰氏阴性菌病方面的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005006899A1 (en) | 2005-01-27 |
| CL2004001702A1 (es) | 2005-05-13 |
| ZA200505957B (en) | 2006-11-29 |
| BRPI0412255A (pt) | 2006-09-19 |
| JP2006528171A (ja) | 2006-12-14 |
| EP1656183A1 (en) | 2006-05-17 |
| UA79674C2 (en) | 2007-07-10 |
| MXPA05014200A (es) | 2006-07-03 |
| GB0317227D0 (en) | 2003-08-27 |
| CA2533177A1 (en) | 2005-01-27 |
| ATE380048T1 (de) | 2007-12-15 |
| EP1656183B1 (en) | 2007-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA06014798A (es) | Antagonistas del receptor de hormona para liberar gonadotropina. | |
| MXPA03007513A (es) | Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato. | |
| TW200510301A (en) | Novel compounds | |
| TW200510303A (en) | Novel compounds | |
| SG122820A1 (en) | Process for the distillation of a mixture of isomeric diisocyanatodiphenylmethanes | |
| TW200407305A (en) | Novel compounds | |
| TNSN07195A1 (en) | Potentiators of glutamate receptors | |
| IL181473A0 (en) | Humanized anti-beta 7 antagonists and uses therefor | |
| EA200901099A1 (ru) | Соединения и способы модулирования сопряженных с g-белком рецепторов | |
| NO20050471L (no) | Fremgangsmate for telomerisasjon av ikke-sykliske olefiner | |
| CL2004000545A1 (es) | Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul | |
| TW200420543A (en) | Treatment of female sexual dysfunction | |
| TW200621244A (en) | Modulators of muscarinic receptors | |
| WO2004056763A3 (en) | Novel glucagon antagonists | |
| TW200800959A (en) | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor | |
| MXPA05011630A (es) | Metodo para aumentar la hidrofobicidad de la superficie de las tazas de inodoro. | |
| IL164016A0 (en) | Azetidine derivatives as ccr-3 receptor antagonists | |
| GB0317227D0 (en) | Treatment of male sexual dysfunction | |
| WO2002100350A3 (en) | Dopamine receptor ligands and therapeutic methods based thereon | |
| PT1673354E (pt) | Arilindenopiridinas e arilindenopirimidinas e sua utilização como antagonistas do receptor da adenosina a2a | |
| WO2007014263A3 (en) | Octahydroisoquinoline compounds as opioid receptor modulators | |
| TW200606145A (en) | Asymmetric hydrogenation process | |
| MXPA05012572A (es) | Derivado de 5-h-benzo[d]naft[2,1-b]azepina como antagonistas selectivos del receptor d1/d5 para el tratamiento de la obesidad y trastornos del sistema nervioso central. | |
| MX2007006382A (es) | Moduladores de receptores muscarinicos. | |
| WO2004103289A3 (en) | Driverse thyroid hormone receptor antagonists and uses thereof |